Onkologie. 2009:3(6):343-347

Pheochromocytoma

doc. MUDr. Tomáš Zelinka, CSc1, Hana Turková3, doc. MUDr. Jiří Widimský CSc2,3
1 3. interní klinika VFN, Centrum pro diagnostiku a léčbu hypertenze, Praha
2 III. interní klinika VFN a 1. LF UK, Praha
3 III. interní klinika VFN a 1. LF UK, Praha, Centrum pro výzkum, diagnostiku a terapii arteriální hypertenze

Pheochromocytomas and functional paragangliomas are catecholamine-producing tumors which present mostly with headache,

sweating, palpitations, and hypertension. Biochemical testing for pheochromocytoma is mandatory not only in subjects with clinical

suspicion for pheochromocytoma but also in subjects with incidentally discovered adrenal mass or in subjects with genetic predisposition.

Computed tomography, magnetic resonance imaging and functional imaging with [123I]-metaiodobenzylguanidine may be used

for tumor localization. Medical pre-treatment is essential for successful operation which is

Keywords: pheochromocytoma, functional paranglioma, endocrine hypertension.

Published: January 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zelinka T, Turková H, Widimský J. Pheochromocytoma. Onkologie. 2009;3(6):343-347.
Download citation

References

  1. Karagiannis A, Mikhailidis DP, Athyros VG, Harsoulis F. Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer 2007; 14: 935-956. Go to original source... Go to PubMed...
  2. Zelinka T, Widimský J jr. Endokrinní hypertenze. In: Widimský J, ed. Hypertenze. Praha: Triton, 2008: 639-666.
  3. Kopetschke R, Slisko M, Kilisli A, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol 2009; 161: 355-361. Go to original source... Go to PubMed...
  4. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007; 14(3): 569-585. Go to original source... Go to PubMed...
  5. Tischler AS. Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch Pathol Lab Med 2008; 132: 1272-1284. Go to original source...
  6. Zelinka T, Timmers HJ, Kozupa A, et al. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: Specific implications for SDHB gene mutations. Endocrine Related Cancer 2008; 15: 311-323. Go to original source... Go to PubMed...
  7. van Nederveen FH, Gaal J, Favier J, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009; 10(8): 764-771. Go to original source... Go to PubMed...
  8. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346: 1459-1466. Go to original source... Go to PubMed...
  9. Pacák K. Feochromocytom. Praha: Galén, 2008.
  10. Zelinka T, Eisenhofer G, Pacák K. Pheochromocytoma as a catecholamine producing tumor: Implications for clinical practice. Stress 2007; 10(2): 195-203. Go to original source... Go to PubMed...
  11. Lenders JW, Pacák K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? Jama 2002; 287: 1427-1434. Go to original source... Go to PubMed...
  12. Pacák K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007; 3: 92-102. Go to original source... Go to PubMed...
  13. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003; 88: 2656-2666. Go to original source... Go to PubMed...
  14. Baid SK, Lai EW, Wesley RA, et al. Brief Communication: Radiographic Contrast Infusion and Catecholamine Release in Patients With Pheochromocytoma. Ann Intern Med 2009; 150: 27-32. Go to original source... Go to PubMed...
  15. Ilias I, Chen CC, Carrasquillo JA, et al. Comparison of 6-18 F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 2008; 49: 1613-1619. Go to original source... Go to PubMed...
  16. Gonias S, Goldsby R, Matthay KK, et al. Phase II study of high-dose [131I]-metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009; 27: 4162-4168. Go to original source... Go to PubMed...
  17. Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 2008; 113: 2020-2028. Go to original source... Go to PubMed...
  18. Joshua AM, Ezzat S, Asa SL, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 2009; 94: 5-9. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.